Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?

Abstract Background Bordetella pertussis infection is a known trigger of atypical hemolytic uremic syndrome (HUS). For patients suspected of having atypical HUS, prompt plasma exchange/infusion (PE/PI) or eculizumab (ECZ) treatment is recommended. Case presentation We report a 1-month-old female inf...

Full description

Bibliographic Details
Main Authors: Ken Saida, Masao Ogura, Yuji Kano, Shingo Ishimori, Takahisa Yoshikawa, Hiroko Nagata, Mai Sato, Koichi Kamei, Kenji Ishikura
Format: Article
Language:English
Published: BMC 2018-12-01
Series:BMC Nephrology
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12882-018-1168-y
id doaj-e17056703b114332a6e3665e731e3504
record_format Article
spelling doaj-e17056703b114332a6e3665e731e35042020-11-25T02:55:11ZengBMCBMC Nephrology1471-23692018-12-011911410.1186/s12882-018-1168-yTreatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?Ken Saida0Masao Ogura1Yuji Kano2Shingo Ishimori3Takahisa Yoshikawa4Hiroko Nagata5Mai Sato6Koichi Kamei7Kenji Ishikura8Division of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDepartment of Pediatrics, Kakogawa Central City HospitalDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentDivision of Nephrology and Rheumatology, National Center for Child Health and DevelopmentAbstract Background Bordetella pertussis infection is a known trigger of atypical hemolytic uremic syndrome (HUS). For patients suspected of having atypical HUS, prompt plasma exchange/infusion (PE/PI) or eculizumab (ECZ) treatment is recommended. Case presentation We report a 1-month-old female infant who was admitted with a severe cough and a B. pertussis-positive sputum culture. She was born at 38 weeks gestation and did not have a family history of renal diseases. Hemophagocytic syndrome was suspected and she was transferred to our hospital 17 days after her initial admission. One day later, she developed acute kidney injury and was diagnosed with HUS triggered by B. pertussis infection. Her plasma complement levels were low and her kidney function continued to worsen over the next few days. However, prior to starting ECZ treatment, her kidney function improved spontaneously; she did not receive PE/PI or ECZ. She was discharged 46 days after her initial hospitalization, without complications. A genetic workup revealed no mutations in CFH, CFI, CFB, C3, MCP, THBD, or DGKE. Conclusions This case demonstrates that B. pertussis infection-related HUS may resolve spontaneously. The decision to treat during the acute phase is challenging because B. pertussis often affects infants suspected of having atypical HUS. However, ECZ may not be the first treatment option for patients with B. pertussis infection-related HUS unless they show an indicated genetic abnormality; if ECZ is used, early discontinuation should be considered.http://link.springer.com/article/10.1186/s12882-018-1168-yAtypical hemolytic uremic syndromeBordetella pertussisEculizumabPlasma exchange
collection DOAJ
language English
format Article
sources DOAJ
author Ken Saida
Masao Ogura
Yuji Kano
Shingo Ishimori
Takahisa Yoshikawa
Hiroko Nagata
Mai Sato
Koichi Kamei
Kenji Ishikura
spellingShingle Ken Saida
Masao Ogura
Yuji Kano
Shingo Ishimori
Takahisa Yoshikawa
Hiroko Nagata
Mai Sato
Koichi Kamei
Kenji Ishikura
Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
BMC Nephrology
Atypical hemolytic uremic syndrome
Bordetella pertussis
Eculizumab
Plasma exchange
author_facet Ken Saida
Masao Ogura
Yuji Kano
Shingo Ishimori
Takahisa Yoshikawa
Hiroko Nagata
Mai Sato
Koichi Kamei
Kenji Ishikura
author_sort Ken Saida
title Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
title_short Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
title_full Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
title_fullStr Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
title_full_unstemmed Treatment of hemolytic uremic syndrome related to Bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
title_sort treatment of hemolytic uremic syndrome related to bordetella pertussis infection —is plasma exchange or eculizumab use necessary?
publisher BMC
series BMC Nephrology
issn 1471-2369
publishDate 2018-12-01
description Abstract Background Bordetella pertussis infection is a known trigger of atypical hemolytic uremic syndrome (HUS). For patients suspected of having atypical HUS, prompt plasma exchange/infusion (PE/PI) or eculizumab (ECZ) treatment is recommended. Case presentation We report a 1-month-old female infant who was admitted with a severe cough and a B. pertussis-positive sputum culture. She was born at 38 weeks gestation and did not have a family history of renal diseases. Hemophagocytic syndrome was suspected and she was transferred to our hospital 17 days after her initial admission. One day later, she developed acute kidney injury and was diagnosed with HUS triggered by B. pertussis infection. Her plasma complement levels were low and her kidney function continued to worsen over the next few days. However, prior to starting ECZ treatment, her kidney function improved spontaneously; she did not receive PE/PI or ECZ. She was discharged 46 days after her initial hospitalization, without complications. A genetic workup revealed no mutations in CFH, CFI, CFB, C3, MCP, THBD, or DGKE. Conclusions This case demonstrates that B. pertussis infection-related HUS may resolve spontaneously. The decision to treat during the acute phase is challenging because B. pertussis often affects infants suspected of having atypical HUS. However, ECZ may not be the first treatment option for patients with B. pertussis infection-related HUS unless they show an indicated genetic abnormality; if ECZ is used, early discontinuation should be considered.
topic Atypical hemolytic uremic syndrome
Bordetella pertussis
Eculizumab
Plasma exchange
url http://link.springer.com/article/10.1186/s12882-018-1168-y
work_keys_str_mv AT kensaida treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT masaoogura treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT yujikano treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT shingoishimori treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT takahisayoshikawa treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT hirokonagata treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT maisato treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT koichikamei treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
AT kenjiishikura treatmentofhemolyticuremicsyndromerelatedtobordetellapertussisinfectionisplasmaexchangeoreculizumabusenecessary
_version_ 1724717778697453568